Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (318)	6/16/1999 1:07:00 AM
From: Walkingshadow	Respond to of 3044

Rick-- Hmm..... FIVE questions. Okay: <<Is this how the release read??>> Answer: No. <<No?>> Answer: No. <<Do us a favor and pop back into the BGEN thread (that's BGEN for Biogen) and flesh out that CRF post, would you please?>> Answer: No. [and that's CHF, for congestive heart failure] <<Are you hottest for endothelin A receptor antagonists?>> Answer: No. <<What are those existing therapies that you think so highly of?>> Answer: Briefly, there are many, often grouped by hemodynamic effect, mode of action, or chemical nature. Examples include nitrates of various types, afterload reducing agents, preload reducing agents, direct SMC (that stands for smooth muscle cell) relaxing agents, diuretics, beta blocking agents (both specific and nonspecific), morphine, mild inotropes such as low dose dopamine or dobutamine. These are effective therapies in most cases. <<Thanks>> Response: Noworries, mite. Walkingshadow